Nov 07, 2008 (Datamonitor via COMTEX) -- NVO | Quote | Chart | News | PowerRating -- Denmark-based healthcare company Novo Nordisk has announced a major investment of around $400 million in a new insulin production plant in Tianjin, China. The plant has been designated Novo Nordisk's primary production base in the Asia Pacific region and will supply both China and export markets.
